Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07122648) titled 'Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory Polymyositis or Dermatomyositis' on Aug. 7.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Paean Biotechnology Inc.
Condition:
Polymyositis
Dermatomyositis
Intervention:
Biological: placebo
Biological: PN-101
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: December 2025
Target Sample Size: 36
Countries of Recruitment:
K...